Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel polymeric nanoparticle - Samyang Biopharmaceuticals

Next Previous
X
Search
Drug Profile

Docetaxel polymeric nanoparticle - Samyang Biopharmaceuticals

Alternative Names: B 5927; Docetaxel-PNP; Nanoparticle docetaxel - Samyang; Nanopolymer docetaxel - Samyang; SYP-0709; SYP-0709S

Latest Information Update: 22 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation; Samyang Group
  • Developer Samyang Biopharmaceuticals Corporation
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 22 Aug 2023 SYP 1261 is still in phase I trial for Solid tumours in South Korea (Samyang Biopharmaceuticals Corporation pipeline, August 2023)
  • 28 May 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in South Korea
  • 17 May 2021 Docetaxel nanopolymeric is still in phase I development for Solid tumours in South Korea (Samyang Biopharmaceuticals Corporation pipeline, May 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top